NFKB1 and neoplasm: Mutations targeting components of the BCR-dependent NF-kB pathway (PRKCB, BCL10, TNFAIP3, TNIP1) occur in over 50% of cases predicting that these tumours rely on B-cell receptor-dependent NF-κB activation and could be vulnerable to antagonists of B-cell receptor signalling (6).